Tolero Pharmaceuticals, Inc., to Present at Biotech Showcase™ 2015
Salt Lake City, Utah - January 9, 2015 - Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, today announced that a member of senior management will present at the Biotech Showcase™ 2015 Conference taking place January 12-14, 2015, in San Francisco, CA. The presentation will include an overview of the Company's lead candidate, alvocidib, a multi cyclin-dependent kinase (CDK) inhibitor, expected to enter Phase 3 studies for the treatment of acute myeloid leukemia (AML) in 2H2015.
Details of the presentation are as follows:
|Event:||Biotech Showcase™ 2015 Conference|
|Date:||Monday, January 12, 2015|
|Time:||1:45 PM, PST|
|Location:||Parc 55 Wyndham San Francisco Union Square Hotel|
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control.
Tolero Pharmaceuticals, Inc.